RedHill Biopharma to Present Opaganib at U.S. Defense Conference
Company Announcements

RedHill Biopharma to Present Opaganib at U.S. Defense Conference

RedHill Biopharma (RDHL) has released an update.

RedHill Biopharma has been selected to present its promising drug, Opaganib, at a U.S. government conference focused on chemical, biological, radiological, and nuclear defense. Opaganib, an investigational drug with antiviral, anticancer, and anti-inflammatory properties, has shown significant potential in treating various conditions, including COVID-19 and Ebola. This presentation opportunity underscores RedHill’s growing collaborations with U.S. agencies and highlights Opaganib’s potential as a versatile medical countermeasure.

For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskRedHill Biopharma and Duke Collaborate on Opaganib Development
TheFlyRedHill Biopharma signs research pact with Duke University School of Medicine
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App